CD226 and B-cell chronic lymphocytic leukemia: A recent study demonstrated that CLL and RS neoplastic cells express TIGIT and CD226, and suggested the existence of an activation and deactivation model analogous to that of T cells also in RS tumor cells, where CD226 might activate neoplastic B cells, enhancing the BCR signaling through the binding with CD155 [87].